Tharimmune, Inc. - Common Stock (THAR)

Tharimmune, Inc. (NASDAQ:THAR) shares initially traded higher on Monday, but have since reversed after the company presented clinical data at the 75th American Association for the Study of Liver Disease (AASLD) meeting. Here's what you need to know.

Tharimmune just reported results for the second quarter of 2024.

Tharimmune shares are trading lower by 16.4% during Wednesday's session. The company announced a 1-for-15 reverse stock split.

Tharimmune, Inc. (NASDAQ:THAR) shares are moving higher on Wednesday after the company announced it received overall positive feedback from the European Medicines Agency (EMA) on its TH104 clinical program.

Tharimmune just reported results for the fourth quarter of 2023.

Tharimmune shares are trading lower by 30% during Monday's session. The company late Friday announced it had entered into an "at the market" offering agreement.

Verastem stock is down on Friday with heavy trading of VSTM shares alongside its latest pancreatic cancer clinical trial safety data.

Sensei Biotherapeutics stock is falling on Friday as SNSE investors are unimpressed by its latest clinical trial data.

Tharimmune stock is on the move Friday as investors prepare for a reverse split of THAR shares after markets close today.

We're diving into the biggest pre-market stock movers that traders need to know about on Friday morning with all of the latest news!

Tharimmune achieves success in Phase 1 trial for TH104, a buccal film with nalmefene. Encouraging safety profile and potential for liver-related conditions.